Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Maintenance therapy after autologous stem cell transplantation, as well as continuous regimens for older, transplant ineligible patients, are emerging as an effective strategy to control the minimal residual disease that persists after response to initial treatments and is the main cause of relapse in patients affected by multiple myeloma (MM). However, though such approaches have consistently demonstrated in clinical trials to be able to delay disease recurrence, thus improving progression-free survival and, at least in some studies, overall survival, the use of these long term therapies (LTTs) in the daily clinical practice is not uniformly applied and some questions remains unanswered. This article aims to provide a synthetic discussion of the most consistent data on novel agent-based LTTs in newly diagnosed MM, to recognize the best candidate for these treatments and to describe a landscape of their possible future application.
a Scientific Direction, Referral Cancer Center of Basilicata , IRCCS-CROB , Rionero in Vulture , Italy.
Pellegrino
P
Musto
b Department of Hematology, Bone Marrow Transplantation Unit , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.
Vittorio
V
Montefusco
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D000077269:Lenalidomide; D060046:Maintenance Chemotherapy; D009101:Multiple Myeloma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018365:Neoplasm, Residual / Q000473:pathology / Q000628:therapy; D019233:Retreatment; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide
Multiple myeloma; bortezomib; carfilzomib; continuous therapy; daratumumab; elotuzumab; ixazomib; lenalidomide; maintenance therapy; minimal residual disease; thalidomide